2 results
DDAVP treatment combined with FVIII clotting factor concentrates in patients with mild hemophilia A.
Primary objectives:To assess the proportion of non-severe hemophilia A patients within FVIII target levels with the DDAVP and FVIII concentrate combination treatment in the first 72 hours after the start of combination treatment, without adding off-…
Approved WMORecruiting
The VOLT CE Mark study will collect data to demonstrate that the Volt PFA System is functioning as intended in a clinical setting and to demonstrate acute safety and effectiveness for the treatment of symptomatic, recurrent paroxysmal atrial…